Regentis Biomaterials AGM approves 14 proposals

Regentis Biomaterials Ltd. reports that its Adjourned Annual General Meeting of Shareholders held on July 9, 2026 approved all fourteen proposals presented to shareholders.

Accepted by SEC EDGAR 07/09/2026 - 04:30 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

Regentis Biomaterials Ltd. reports that its Adjourned Annual General Meeting of Shareholders held on July 9, 2026 approved all fourteen proposals presented to shareholders. The proposals, which were outlined in the company’s May 28, 2026 Notice and Proxy Statement and a June 4, 2026 amended notice, each received the required majority support.

Key Terms

Form 6-K, Foreign Private Issuer, Adjourned Annual General Meeting of Shareholders, Notice and Proxy Statement, +1 more

5 terms

Form 6-K regulatory

"Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16"

A Form 6-K is a report that companies listed in certain countries file to provide important updates, such as financial results, corporate changes, or other significant information, to regulators and investors. It functions like an official company update or news release, helping investors stay informed about developments that could affect their investment decisions.

Foreign Private Issuer regulatory

"Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16"

A foreign private issuer is a company organized outside the United States that meets tests showing it is primarily foreign-controlled and therefore qualifies for a different set of U.S. reporting rules. For investors, that means the company files less frequent or differently formatted disclosures with U.S. regulators and may follow home-country accounting and governance practices, so buying its stock is like dining at a well-reviewed restaurant that follows its home kitchen’s rules instead of the local menu — you get access but should check what standards apply.

Adjourned Annual General Meeting of Shareholders financial

"On July 9, 2026, the Adjourned Annual General Meeting of Shareholders of Regentis Biomaterials Ltd."

Notice and Proxy Statement regulatory

"Each of those proposals was described in the Company’s Notice and Proxy Statement"

Form 6-K/A regulatory

"Amended Notice and Proxy Statement attached as Exhibit 99.1 to the Company’s Form 6-K/A"

Form 6-K/A is an amended report filed with the U.S. Securities and Exchange Commission by a foreign (non‑U.S.) company to correct or add material information previously sent in a Form 6‑K. It matters to investors because it updates the official public record—think of it as a corrected or expanded page in a company’s disclosure file—so the new or corrected details can affect how investors judge the company’s risks, results or future prospects.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Regentis Biomaterials Ltd. (RGNT) announce in its July 2026 Form 6-K?

Regentis Biomaterials Ltd. announced that shareholders approved all fourteen proposals at its Adjourned Annual General Meeting held on July 9, 2026. Each proposal received the required majority, following prior disclosure in the company’s May 28, 2026 proxy materials and a June 4, 2026 amendment.

How many proposals were approved at Regentis Biomaterials Ltd.’s 2026 Adjourned Annual General Meeting?

Shareholders approved fourteen proposals at the Adjourned Annual General Meeting of Regentis Biomaterials Ltd. on July 9, 2026. The filing notes that every proposal described in the company’s proxy and amended proxy materials obtained the majority needed for approval under the stated voting requirements.

When was Regentis Biomaterials Ltd.’s 2026 Adjourned Annual General Meeting held?

The Adjourned Annual General Meeting took place on July 9, 2026 for Regentis Biomaterials Ltd. According to the Form 6-K, shareholders considered fourteen proposals at that meeting, all of which were approved by the required majority after earlier proxy materials were circulated.

Where were the details of Regentis Biomaterials Ltd. (RGNT) AGM proposals originally described?

The fourteen proposals were described in a May 28, 2026 Notice and Proxy Statement for Regentis Biomaterials Ltd.’s Annual General Meeting. An Amended Notice and Proxy Statement dated June 4, 2026, both furnished on Forms 6-K and 6-K/A, provided the final proposal descriptions.

What type of SEC reporting framework does Regentis Biomaterials Ltd. (RGNT) follow?

Regentis Biomaterials Ltd. files its annual reports on Form 20-F as a foreign private issuer. This Form 6-K is a report of a foreign private issuer under Exchange Act Rules 13a-16 or 15d-16, used to furnish current information like shareholder meeting results.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K

Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16

of the Securities Exchange Act of 1934

For the month of July 2026

Commission File Number: 001-42834

Regentis Biomaterials Ltd.

(Translation of registrant’s name into English)

60 Medinat Hayehudim Street, Herzliya 4676652

Israel

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F ☒      Form 40-F ☐

On July 9, 2026, the Adjourned Annual General Meeting of Shareholders of Regentis Biomaterials Ltd. (the “Company”) approved each of the fourteen proposals brought before the Company’s shareholders at the meeting, in accordance with the majority required for each proposal. Each of those proposals was described in the Company’s Notice and Proxy Statement with respect to the Company’s Annual General Meeting of Shareholders, dated May 28, 2026, attached as Exhibit 99.1 to the Company’s Form 6-K that was furnished to the U.S. Securities and Exchange Commission on May 28, 2026, as amended by the Amended Notice and Proxy Statement attached as Exhibit 99.1 to the Company’s Form 6-K/A that was furnished to the U.S. Securities and Exchange Commission on June 4, 2026.

1

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	Regentis Biomaterials Ltd.
Date: July 9, 2026	/s/ Ehud Geller
	Ehud Geller
	Chairman and Chief Executive Officer

2